Austin Frakt, New York Times contributor and director of the Partnered Evidence-Based Policy Resource Center at the V.A. Boston Healthcare System, examines America’s No. 2 killer among illicit drugs in the United States: cocaine. Frakt shares, “The surge in cocaine deaths has received relatively little attention. The trouble is, there’s a lot less we can do for cocaine than opioids.” This is a pertinent piece that explores the importance of developing effective therapies for the treatment of cocaine use disorder.
The opioid crisis clearly has outpaced all other topics as the story of the year in addiction, and 2018 promises a repeat. Yet with all the justifiable attention to opioid addiction and overdose, is there danger that the next lurking trend in substance use, cocaine and methamphetamine, will emerge as a full-blown epidemic before enough people notice?
Michael Detke, M.D., Ph.D., Embera’s Chief Medical Officer, will moderate the “Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis” panel at 2018 BIO CEO & Investor Conference. The panel will be held on Tuesday, February 13, 2018, at 9 a.m. EST at the New York Marriott Marquis in New York City.